熱門資訊> 正文
ANI Pharma购买与Iluvien和Yutiq相关的版税
2025-03-18 19:46
- ANI Pharmaceuticals (NASDAQ:ANIP) announced Tuesday it has completed the purchase of royalty obligations linked to Iluvien and Yutiq, two eye disease therapies the company added with its $5.50 per share acquisition of Alimera Sciences in 2024.
- Accordingly, ANI Pharmaceuticals (NASDAQ:ANIP) will not be required to pay the 3.125% perpetual royalties based on Iluvien and Yutiq global revenues to SWK Funding LLC with effect from Jan. 1, 2025.
- The company has made a one-time payment of $17.25M using its cash on hand to complete the transaction.
- With its Q4 2024 financials, ANIP said it has made substantial progress toward ensuring supply security for Iluvien and Yutiq, which it expects could generate $97M-$103M in net revenue in 2025 compared to $32M last year.
More on ANI Pharmaceuticals
- ANI Pharmaceuticals, Inc. (ANIP) Q4 2024 Earnings Call Transcript
- ANI Pharmaceuticals: More Than Just A Generics Company
- ANI Pharma wins Overweight rating at J.P. Morgan on growth prospects
- ANI Pharmaceuticals beats top-line and bottom-line estimates; updates FY25 outlook
- Seeking Alpha’s Quant Rating on ANI Pharmaceuticals
推薦文章
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
